[go: up one dir, main page]

CY1110631T1 - Διαλυτοποιημενα δηλητηρια τοποϊσομερασης - Google Patents

Διαλυτοποιημενα δηλητηρια τοποϊσομερασης

Info

Publication number
CY1110631T1
CY1110631T1 CY20101100388T CY101100388T CY1110631T1 CY 1110631 T1 CY1110631 T1 CY 1110631T1 CY 20101100388 T CY20101100388 T CY 20101100388T CY 101100388 T CY101100388 T CY 101100388T CY 1110631 T1 CY1110631 T1 CY 1110631T1
Authority
CY
Cyprus
Prior art keywords
formula
poetry
points
compounds
preparing compounds
Prior art date
Application number
CY20101100388T
Other languages
English (en)
Inventor
Edmond J Lavoie
Alexander L Ruchelman
Leroy F Liu
Original Assignee
Rutgers, The State University
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Rutgers, The State University filed Critical Rutgers, The State University
Publication of CY1110631T1 publication Critical patent/CY1110631T1/el

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
    • C07D491/12—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains three hetero rings
    • C07D491/14—Ortho-condensed systems
    • C07D491/147—Ortho-condensed systems the condensed system containing one ring with oxygen as ring hetero atom and two rings with nitrogen as ring hetero atom
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
    • C07D491/12—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains three hetero rings
    • C07D491/14—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/10—Antimycotics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P33/00—Antiparasitic agents
    • A61P33/02—Antiprotozoals, e.g. for leishmaniasis, trichomoniasis, toxoplasmosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
    • C07D491/22—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains four or more hetero rings

Landscapes

  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Virology (AREA)
  • Dermatology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Saccharide Compounds (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
  • Enzymes And Modification Thereof (AREA)
  • Agricultural Chemicals And Associated Chemicals (AREA)
  • Toys (AREA)
  • Meat, Egg Or Seafood Products (AREA)
  • Confectionery (AREA)

Abstract

Η εφεύρεση παρέχει ενώσεις του χημικού τύπου (I) στον οποίον τα Α, Β, W, Υ, Ζ, και R1 έχουν την οποιανδήποτε εκ των εννοιών που καθορίζονται σύμφωνα με την προδιαγραφή και τα φαρμακευτικώς αποδεκτά άλατα αυτών. Η εφεύρεση παρέχει επίσης φαρμακευτικές συνθέσεις περιλαμβάνοντας μία ένωση του χημικού τύπου I, διεργασίες για την παρασκευή των ενώσεων του χημικού τύπου I, ενδιάμεσα προϊόντα που είναι χρήσιμα για την παρασκευή των ενώσεων του χημικού τύπου I, και θεραπευτικές μεθόδους για την αγωγή του καρκίνου χρησιμοποιώντας τις ενώσεις του χημικού τύπου I.
CY20101100388T 2001-11-14 2010-05-03 Διαλυτοποιημενα δηλητηρια τοποϊσομερασης CY1110631T1 (el)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US33273401P 2001-11-14 2001-11-14
EP02801198A EP1465625B1 (en) 2001-11-14 2002-11-14 Solubilized topoisomerase poisons

Publications (1)

Publication Number Publication Date
CY1110631T1 true CY1110631T1 (el) 2015-04-29

Family

ID=23299632

Family Applications (1)

Application Number Title Priority Date Filing Date
CY20101100388T CY1110631T1 (el) 2001-11-14 2010-05-03 Διαλυτοποιημενα δηλητηρια τοποϊσομερασης

Country Status (15)

Country Link
US (4) US7049315B2 (el)
EP (3) EP2286812A1 (el)
JP (3) JP4628675B2 (el)
KR (1) KR20050044491A (el)
AT (1) ATE456952T1 (el)
AU (1) AU2002363658B2 (el)
CA (1) CA2467774C (el)
CY (1) CY1110631T1 (el)
DE (1) DE60235287D1 (el)
DK (1) DK1465625T3 (el)
ES (1) ES2340473T3 (el)
MX (1) MXPA04004606A (el)
PT (1) PT1465625E (el)
SI (1) SI1465625T1 (el)
WO (1) WO2003041660A2 (el)

Families Citing this family (21)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ATE405568T1 (de) 2001-11-14 2008-09-15 Univ Rutgers Cytotoxische mittel
EP1453506B1 (en) 2001-11-14 2008-04-02 Rutgers, The State University Topoisomerase poison agents
DE60231426D1 (de) 2001-11-14 2009-04-16 Univ Rutgers Solubilisierte topoisomerase-gift-mittel
DE60235287D1 (de) 2001-11-14 2010-03-25 Univ Rutgers Löslich gemachte topoisomerase-gifte
US6992088B2 (en) * 2002-08-09 2006-01-31 Rutgers, The State University Of New Jersey Nitro and amino substituted heterocycles as topoisomerase I targeting agents
AU2003268075A1 (en) * 2002-08-09 2004-02-25 Edmond J. Lavoie Nitro and amino substituted dibenzonaphthyridines as topoisomerase agents
WO2004014918A1 (en) 2002-08-09 2004-02-19 Rutgers, The State University Nitro and amino substituted topoisomerase agents
AU2003290818A1 (en) 2002-11-12 2004-06-03 Edmond J. Lavoie Topoisomerase-targeting agents
CA2573190A1 (en) * 2004-07-09 2006-01-26 Medisyn Technologies, Inc. Mt477 and related compounds for the treatment of various cancers
CN101505599A (zh) * 2006-05-24 2009-08-12 雷迪博士实验室有限公司 5(s)-(2′-羟基乙氧基)-20(s)-喜树碱及其制备和治疗癌症的应用
CN102256966B (zh) 2008-10-17 2016-02-10 白头生物医学研究所 可溶性mTOR复合物和其调节剂
TW201038578A (en) * 2009-01-30 2010-11-01 Univ Rutgers Methods to treat cancer
ES2401563T3 (es) 2009-03-06 2013-04-22 Rutgers, The State University Of New Jersey Derivados de metilendioxibenzo [I]fenantridina usados para tratar el cáncer
WO2010127363A1 (en) 2009-05-01 2010-11-04 Rutgers, The State University Of New Jersey Toposiomerase inhibitors
WO2010127360A1 (en) * 2009-05-01 2010-11-04 Rutgers, The State University Of New Jersey Toposiomerase inhibitors
WO2012015875A1 (en) * 2010-07-28 2012-02-02 Genzyme Corporation Methods for treating hematological malignancies
WO2012015901A1 (en) * 2010-07-28 2012-02-02 Genzyme Corporation Methods for treating gastric and pancreatic malignancies
US9879003B2 (en) 2012-04-11 2018-01-30 Dana-Farber Cancer Institute, Inc. Host targeted inhibitors of dengue virus and other viruses
WO2014063054A1 (en) 2012-10-19 2014-04-24 Dana-Farber Cancer Institute, Inc. Bone marrow on x chromosome kinase (bmx) inhibitors and uses thereof
CA3019945A1 (en) 2016-04-04 2017-10-12 Rutgers, The State University Of New Jersey Topoisomerase poisons
CN111925370B (zh) * 2020-09-01 2023-07-21 湖北科苑生物药业有限公司 一种吡嗪并吡唑并萘啶类化合物及其制备方法与应用

Family Cites Families (54)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US2981731A (en) 1961-04-25 Acridine derivatives
US2985681A (en) * 1953-08-28 1961-05-23 Knoll Ag Phenylacetic acid and aminoalkyl esters thereof
US2985661A (en) 1956-02-06 1961-05-23 American Cyanamid Co Preparation of 2(omicron-aminophenyl)-benzimidazole
US2915523A (en) 1956-12-03 1959-12-01 Parke Davis & Co Benzacridine compounds
US3272707A (en) 1964-07-17 1966-09-13 Smith Kline French Lab Pharmaceutical compositions and methods for their use
CH420045A (de) 1964-09-01 1967-03-15 Ciba Geigy Verwendung von neuen Poly-azolen als optische Aufhellmittel für textile organische Materialien
US3267107A (en) 1964-09-17 1966-08-16 American Home Prod 3-(4'-5'-methylenedioxy-phenyl)-7, 8-dimethoxy-1, 2, 3, 4,-tetrahydroisoquinolines
US3849561A (en) 1964-10-20 1974-11-19 S Naruto Anti-peptic ulcer substance from corydalis tubers
DE1670684A1 (de) 1966-04-01 1970-12-03 Hoechst Ag Verfahren zur Herstellung von basisch substituierten Bis-benzimidazol-derivaten
US3542782A (en) 1967-03-15 1970-11-24 Sandoz Ag 5,6-dihydro-8h-isoquino(1,2-b)quinazolines
JPS4942700A (el) 1972-08-25 1974-04-22
US3912740A (en) 1974-02-28 1975-10-14 Us Health Method for the preparation of oxygenated benzo{8 c{9 phenanthridine compounds
PT73763B (fr) 1981-10-01 1983-10-26 Quatrum Empresa Nacional De Qu Procede pour la preparation de nouveaux epoxides d'alkaloides benzofenantridiniques et de compositions pharmaceutiques qui les contiennent
US4761417A (en) 1982-05-14 1988-08-02 Maroko Peter R Compounds, compositions and method of treatments for improving circulatory performance
US4980344A (en) 1982-05-14 1990-12-25 Maroko Peter R Compositions for improving circulatory performance
US5153178A (en) 1982-05-14 1992-10-06 Maroko Peter R Compositions and method of treatment for improving circulatory performance
US4749708A (en) 1982-05-14 1988-06-07 Maroko Peter R Composition for improving circulatory performance
IE55519B1 (en) 1982-05-14 1990-10-10 Maroko Peter R Use of a protoberberine alkaloid and composition containing same
US4559157A (en) 1983-04-21 1985-12-17 Creative Products Resource Associates, Ltd. Cosmetic applicator useful for skin moisturizing
LU84979A1 (fr) 1983-08-30 1985-04-24 Oreal Composition cosmetique ou pharmaceutique sous forme aqueuse ou anhydre dont la phase grasse contient un polyether oligomere et polyethers oligomeres nouveaux
JPS61130289A (ja) 1984-11-29 1986-06-18 Ss Pharmaceut Co Ltd １３−プロピルベルベリンの塩
FR2595356B1 (fr) 1986-03-05 1991-05-24 Pasteur Strasbourg Universite Derives des nitro ou aminobenzyltetrahydroisoquinoleines, procedes d'obtention, compositions pharmaceutiques les contenant, proprietes pharmacologiques et applications
US5244903A (en) 1987-03-31 1993-09-14 Research Triangle Institute Camptothecin analogs as potent inhibitors of topoisomerase I
US4820508A (en) 1987-06-23 1989-04-11 Neutrogena Corporation Skin protective composition
SU1530628A1 (ru) 1987-11-20 1989-12-23 Ленинградский Технологический Институт Им.Ленсовета Тригидрохлорид 2-[2-фенил-5(6)-бензимидазолил]-N-(3-диметиламинопропил)-5(6)-бензимидазолкарбоксамида в качестве флуоресцентного красител дл исследовани ДНК
US4992478A (en) 1988-04-04 1991-02-12 Warner-Lambert Company Antiinflammatory skin moisturizing composition and method of preparing same
US4938949A (en) 1988-09-12 1990-07-03 University Of New York Treatment of damaged bone marrow and dosage units therefor
US5106863A (en) 1990-03-26 1992-04-21 Ortho Pharmaceutical Corporation Substituted imidazole and pyridine derivatives
US5135934A (en) 1990-07-06 1992-08-04 Du Pont Merck Pharmaceutical Company 3-phenyl-5,6-dihydrobenz(c) acridine-7-carboxylic acids and related compounds as immunosuppressive agents
US5126351A (en) 1991-01-24 1992-06-30 Glaxo Inc. Antitumor compounds
DE4116593C1 (el) * 1991-05-22 1993-01-07 Fa. Hermann Heye, 3063 Obernkirchen, De
US5223506A (en) 1991-06-04 1993-06-29 Glaxo Inc. Cyclic antitumor compounds
US5428040A (en) 1993-08-31 1995-06-27 The Du Pont Merck Pharmaceutical Company Carbocyclic fused-ring quinolinecarboxylic acids useful as immunosuppressive agents
ATE218551T1 (de) 1993-09-28 2002-06-15 Kyowa Hakko Kogyo Kk Tetracyclische verbindungen
PL324034A1 (en) 1995-05-17 1998-05-11 Univ Rutgers Tribenzimidazoles useful as inhibitors of topoisomerase i
US5807874A (en) 1995-05-17 1998-09-15 Rutgers, The State University Of New Jersey Trisbenzimidazoles useful as topoisomerase I inhibitors
US5767142A (en) 1996-03-20 1998-06-16 Rutgers, The State University Of New Jersey Trisbenzimidazoles useful as topoisomerase I inhibitors
CZ254498A3 (cs) 1996-02-12 1998-12-16 Rutgers, The State University Of New Jersey Analogy coralynu jako inhibitory topoisomerasy
US5770617A (en) 1996-03-20 1998-06-23 Rutgers, The State University Of New Jersey Terbenzimidazoles useful as antifungal agents
CA2266321A1 (en) 1996-09-23 1998-03-26 Rutgers, The State University Of New Jersey Substituted heterocycles as anti-tumor agents
US6140328A (en) * 1997-12-12 2000-10-31 Rutgers, The State University Of New Jersey Heterocyclic cytotoxic agents
DE69940523D1 (de) 1998-10-14 2009-04-16 Purdue Research Foundation Neue indenoisoquinoline als antineoplastische mittel
AU1236401A (en) * 1999-10-29 2001-05-14 Rutgers, The State University Of New Jerey Heterocyclic cytotoxic agents
US6740650B2 (en) 1999-10-29 2004-05-25 Rutgers, The State University Of New Jersey Heterocyclic cytotoxic agents
WO2003041680A1 (en) 2001-11-13 2003-05-22 The Procter & Gamble Company Topical compositions containing enzymes stabilized with inhibitors
DE60231426D1 (de) 2001-11-14 2009-04-16 Univ Rutgers Solubilisierte topoisomerase-gift-mittel
DE60235287D1 (de) 2001-11-14 2010-03-25 Univ Rutgers Löslich gemachte topoisomerase-gifte
EP1453506B1 (en) 2001-11-14 2008-04-02 Rutgers, The State University Topoisomerase poison agents
ATE405568T1 (de) 2001-11-14 2008-09-15 Univ Rutgers Cytotoxische mittel
US6970985B2 (en) * 2002-07-09 2005-11-29 Bluerisc Inc. Statically speculative memory accessing
WO2004014918A1 (en) 2002-08-09 2004-02-19 Rutgers, The State University Nitro and amino substituted topoisomerase agents
US6992088B2 (en) * 2002-08-09 2006-01-31 Rutgers, The State University Of New Jersey Nitro and amino substituted heterocycles as topoisomerase I targeting agents
AU2003268075A1 (en) * 2002-08-09 2004-02-25 Edmond J. Lavoie Nitro and amino substituted dibenzonaphthyridines as topoisomerase agents
AU2003290818A1 (en) * 2002-11-12 2004-06-03 Edmond J. Lavoie Topoisomerase-targeting agents

Also Published As

Publication number Publication date
WO2003041660A3 (en) 2003-10-16
CA2467774A1 (en) 2003-05-22
EP1465625A4 (en) 2005-06-08
JP4628675B2 (ja) 2011-02-09
CA2467774C (en) 2011-09-20
US20110136812A1 (en) 2011-06-09
AU2002363658B2 (en) 2008-09-11
US20090239871A1 (en) 2009-09-24
EP2196205A1 (en) 2010-06-16
DK1465625T3 (da) 2010-05-31
ES2340473T3 (es) 2010-06-04
EP1465625B1 (en) 2010-02-03
JP2005511617A (ja) 2005-04-28
US7517883B2 (en) 2009-04-14
US8389721B2 (en) 2013-03-05
EP2286812A1 (en) 2011-02-23
US20060052381A1 (en) 2006-03-09
SI1465625T1 (sl) 2010-06-30
US20050009824A1 (en) 2005-01-13
US7049315B2 (en) 2006-05-23
KR20050044491A (ko) 2005-05-12
DE60235287D1 (de) 2010-03-25
ATE456952T1 (de) 2010-02-15
EP1465625A2 (en) 2004-10-13
JP2010184942A (ja) 2010-08-26
US7781587B2 (en) 2010-08-24
PT1465625E (pt) 2010-03-09
JP2013166801A (ja) 2013-08-29
WO2003041660A2 (en) 2003-05-22
JP5337104B2 (ja) 2013-11-06
MXPA04004606A (es) 2004-09-10

Similar Documents

Publication Publication Date Title
CY1110631T1 (el) Διαλυτοποιημενα δηλητηρια τοποϊσομερασης
PL367682A1 (en) Dolastatin 10 derivatives
MY136430A (en) N-adamantylmethyl derivatives, pharmaceutical compositions containing them and processes for their preparation
SE0104140D0 (sv) Novel Compounds
ATE296826T1 (de) Pyrazolo(1,5)pyridinderivate
BR0210122A (pt) Composto ou um sal farmaceuticamente aceitável do mesmo, método para o tratamento ou prevenção de uma doença, uso do composto ou de seu sal, e, método para preparar o mesmo
SE0400043D0 (sv) New compounds
MXPA04001968A (es) Agentes antidiabeticos.
EE200000472A (et) Kasvajavastased toimeained
GB0109122D0 (en) Novel compounds
EP1453812A4 (en) CYTOTOXIC AGENTS
ATE390923T1 (de) Topoisomerase-giftmittel
DE60231426D1 (de) Solubilisierte topoisomerase-gift-mittel
AR026267A1 (es) Agentes heterociclicos citotoxicos.
GEP20074058B (en) 4-(7-halo-2-quino(xa) linyloxy-phenoxy-propionic acid derivatives as antineoplastic agents
FI935800A0 (fi) Antidepressiva och mot Parkisons sjukdom verksamma foereningar
WO2004014906A3 (en) Nitro and amino substituted dibenzonaphthyridines as topoisomerase agents
MY139228A (en) Imidazolinylmethyl aralkylsulfonamides
SE0202693D0 (sv) Compounds
SE0202692D0 (sv) Compounds
WO2004044174A3 (en) Topoisomerase-targeting agents
EP1482933A4 (en) SIMPLIFIED AND EFFICIENT DERIVATIVES OF IMMUNOSUPPRESSANT AGENTS
SE0004827D0 (sv) Therapeutic compounds